Page 16 - David Clair News Today

Share this article Share this article MINNEAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.), in the highly rated peer-reviewed journal, Annals of Oncology (link). This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid ...

Share this article Share this article MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple Plex TM immunoassay cartridge portfolio to include nine new cartridge formats. These new cartridge offerings provide Simple Plex users with increased flexibility in the number of samples and biomarker assays run on each cartridge. Simple Plex assay cartridges, run on the Ella TM platform, utilizing ...

Share this article Share this article MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2020. The quarterly dividend will be payable February 26, 2021 to all common shareholders of record on February 12, 2021. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a glob...

Share this article Share this article MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million.   GAAP EPS was $1.15 versus $3.02 one year ago primarily relating to a non-recurring gain of approximately ...

Operator Good morning, and welcome to the Bio-Techne earnings conference call for the Second Quarter of Fiscal Year 2021. [Operator Instructions] I would now like to turn the call over to David Clair, Bio-Technes Senior Director, Investor Relations and Corporate Development. David Clair -- Senior Director, Investor Relations & Corporate Development Good morning, and thank you for joining us. On the call with me this morning are Chuck Kummeth, Chief Executive Officer; and Jim Hippel, Chief Fina...

Share this article Share this article MINNEAPOLIS, Jan. 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced an initial minority strategic equity investment in Changzhou Eminence Biotechnology Co., Ltd. ("Eminence").  Eminence will use the financing proceeds to expand its manufacturing capacity and increase the service capabilities of...

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi, and Wilson Wolf, launches today. The new company brings together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing from its founding partners. ScaleReady provides leading therapeutic developers with the...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf ScaleReadys mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry ScaleReady will provide sales, marketing, and application support for customers globally ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH),...